# How a growth hormone fragment led researchers to a nerve signaling protein

- Article ID: research-031
- Product: AOD-9604 (aod-9604-681, aod-9604-682)
- Canonical page: https://heritagebiolabs.com/research-library/articles/031-how-a-growth-hormone-fragment-led-researchers-to-a-nerve-signaling-protein
- Product collection: https://heritagebiolabs.com/research-library/products/aod-9604
- Product page: https://heritagebiolabs.com/product/aod-9604-681
- Product page: https://heritagebiolabs.com/product/aod-9604-682
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2019, 2021, 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. Some can interact with proteins and change how cells send signals. AOD-9604 is a synthetic 16-amino-acid peptide built from the last 15 amino acids of human growth hormone with an added tyrosine at the front. The same sequence later appeared in research as LAT8881. In 2026, David Spanswick and colleagues used it to investigate a protein involved in heightened sensitivity after nerve injury. [1, 2]

The investigators studied rats with experimentally induced nerve injury and examined signaling in nervous system tissue. They compared LAT8881 with shorter related peptides. For the protein identification step, they attached a light-activated tag to a related short peptide so that it could be linked to a nearby binding protein and recovered from spinal cord material. The experiments pointed to LanCL1. Reducing LanCL1 expression in clusters of sensory nerve cells blocked the tested effect of LAT8881 in the rat model. [1]

Together, these tests support a role for LanCL1 in the model. The binding experiment used a tagged relative of the original 16-amino-acid peptide. The gene-expression experiment then tested the role of the candidate protein in the response to LAT8881 itself. Using complementary methods helped the researchers distinguish a protein that was merely present from one that appeared to matter to the measured response. [1]

The animal outcome concerned experimental sensitivity after nerve injury. A separately registered randomized crossover study in people with neuropathic pain had previously found no significant difference on its main pain-rating measure. The laboratory result identifies a possible mechanism for follow-up, while the clinical registry records what happened when the compound was compared with placebo in people. [1, 3]

## Sources

1. David C. Spanswick et al. Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain. Pain (publication 2026-06-02). <https://pmc.ncbi.nlm.nih.gov/articles/PMC13382871/>
2. U.S. Food and Drug Administration. FDA Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate). Pharmacy Compounding Advisory Committee briefing (publication 2024-12-04). <https://www.fda.gov/media/183584/download>
3. Lateral Pharma Pty Ltd. A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain. ClinicalTrials.gov (publication 2019-03-07, results posted 2021-04-23). <https://clinicaltrials.gov/study/NCT03865953?tab=results>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 007 - AOD-9604.docx; article 31; content SHA-256 959aa0c12a50621162b0c7d54f2c78ff3e99be0d5da6d66a574c1a9c89d501ba.
